

M U N I
S C I

C8116

Antibodies as immunochemical tools

Spring semester 2025


Hans Gorris

Department of Biochemistry

March 4th, 2025

Antigenic determinants: hapten

- Immunization generates antibodies only against large molecules, e.g. proteins
- Antibodies against small molecules (**haptens**) must be produced by coupling (typically derivatized) small molecule **onto the surface** a **large carrier protein**.



Definition of hapten:
A low-molecular weight molecule which contains an antigenic determinant but which is not itself antigenic unless bound to an antigenic carrier


Other examples:
toxins, pharmaceuticals,
hormones...

Polyclonal vs. monoclonal antibodies

polyclonal

Antibodies that are collected from sera of exposed animal

recognize multiple antigenic sites of injected substance



monoclonal


Individual B cell hybridoma is cloned and cultured.
Secreted antibodies are collected from culture media

recognize ONE antigenic site of injected substance




Generation of monoclonal antibodies

=> first described by Köhler/Milstein (1975)




Generation of monoclonal antibodies




Antibodies as immunochemical reagents

=> Antibodies are used as bioanalytical reagents to specifically detect and quantify other molecules



Recombinant antibody fragments



Recombinant antibody fragments

Immortalization of hybridomas through cloning


or

generation of new **antibodies without immunization**

- Greater speed of **production** (*E. coli batch fermentation*)
- New specificities especially for **poor immunogens**
- Possibility to **fine-tune** antibody specificity and affinity
- Possibility to **tailor make** the antibody to perform special tasks
 - tags, handles (for conjugation, immobilization)
 - fusing to other protein (e.g. enzymes)

Likely to be increasingly used in **miniaturised systems** to enable full control of antibody performance.

Heavy chain antibodies




our own most
common antibody


heavy chain antibodies
(velbloud, dromedár, lama)

(žralok)

From heavy chain antibodies to nanobodies




Nanobodies: Detection of hidden epitopes



Advantages of nanobodies

- Mass: ca. 15 kDa (IgG: 150 kDa), 2.5 nm diameter (IgG 15 nm)
- High solubility
- Rapid targeting and fast blood clearance
- Detection of “hidden“ epitopes
- Easy cloning: Recombinant engineering and protein expression *in vitro* in bacterial production systems are much simpler
- Very stable and heat resistant (no cold storage required)
- Simple genetic structure allows easy re-engineering of nanobodies to introduce new antigen-binding characteristics or attach labels


Recombinant nanobodies



a Chromobodies.

b Detection of the nuclear lamina with lamin chromobody in living cells. Confocal images of HeLa cells coexpressing lamin chromobody (*green*) and red fluorescent histone H2B as a mitosis marker. Scale bar: 10 μ m


Phage display using filamentous phage M13



- Infects / replicates in *E. coli*
- Protein coat:
major coat protein: pVIII
minor coat proteins: pIII, pVI, pVII, pIX
- The phage can be engineered to display foreign peptides or proteins as a fusion with one of the coat proteins, most commonly pIII.
- The genomic DNA encoding for the coat proteins is enclosed within the protein coat.
=> Each protein remains connected to its encoding DNA


George Smith / Greg Winter:
Nobel prize in chemistry 2018

Construction of phage displayed protein libraries




Protein engineering by *in vitro* evolution

Selection cycle




Option to introduce random mutations (e.g. error-prone PCR)

Identification of high affinity protein ligands




Single-domain antibody (nanobody)




Problem here:
the genetic information
for Vh and VL need
to be fused to get
functional paratops

Production of recombinant antibodies

Expression system (Gene of Ab fragment known)




Phage display (Gene of Ab fragment unknown)



Alternatives for antibodies

Aptamers

RNA or DNA aptamer




Folding



Complementary
base pairing



Target
binding



Binding through:

- (1) 3-dimensional, shape-dependent interactions
- (2) hydrophobic interactions, base-stacking, intercalation


SELEX*




*systematic evolution
of ligands by exponential
enrichment
=> *in vitro* selection

SELEX*


Step 1: Bind oligonucleotide library and discard non-binder




Step 2: Elute oligonucleotides that bind desired targets



Step 3: Perform PCR to amplify eluted binders




Step 4: Repeat steps 1 through 3 using enriched oligonucleotide pool



Aptamers: Assay designs


Ai

Direct




ii

Sandwich




iii

Competitive




Bi

Conformational Change




ii

Split Aptamers




iii

Target-induced Dissociation and Rolling Circle Amplification (RCA)




Molecularly imprinted polymer (MIP)

“Plastic antibodies”



Immunoassays


Literature for in-depth reading




A rough categorization of immunoassays

HETEROGENEOUS

A




B




sandwich
immunoassay

competitive
immunoassay

C



D



HOMOGENEOUS

Solid phase matrix

in heterogeneous non-competitive sandwich immunoassays

Performance-related issues:

- 1) low background in detection system
- 2) immobilization qualities:
 - high capacity
 - suitable and easy coupling chemistries
 - large surface
 - maintained reactivity of capture protein
 - no leakage
- 3) easy handling
- 4) inert in binding the labelled antibody/analyte => low background
- 5) effectively washed => low background
- 6) antibody excess through **high density** - surface measurement
- 7) antibody excess through **large surface** - integrating measurement


Solid phase matrices

Size	Examples	Advantages	Disadvantages
Small particle / "beads" (< 20 µm)	Latex Microcrystalline cellulose Fine porous glass Magnetic beads Liposomes Starburst™ dendrimers	Dispensing as for liquids Agitation not required High antibody binding capacity	Centrifugation required (unless used with a membrane capture) Long magnetic precipitation
Medium particle (< 1 mm)	Sepharose beads Sephacryl beads Sephadex beads	Centrifugation not required Short magnetic separation	Agitation required Slower binding kinetics than above Moderate antibody binding capacity
Single particle	Beadure™	Centrifugation not required Agitation not required	Some variability in antibody coupling Lower antibody binding capacity Difficulty in dispensing Poor binding kinetics
Fibers	Membranes Glass fibers Nylon Silicon rubber	Centrifugation not required Agitation not required No dispensing of reagent Simple to use	Medium antibody binding capacity Can be fast binding kinetics
Solid surface	Coated tubes Dipsticks Microtiter plates (MTP)	Centrifugation not required Agitation rare No dispensing of reagent Simple to use	Variability in antibody coupling Lowest antibody binding capacity Slowest binding kinetics

Most frequently used solid phase matrices


Non-competitive immunoassay

("sandwich" immunoassay)



Non-competitive immunoassay

a capture antibody specific for a single epitope of the analyte is coated on a solid phase
(e.g. on a microtiter plate)
(=> monoclonal antibody preferred)




Non-competitive immunoassay


analyte



sample containing the analyte (at least two non-overlapping epitopes) is added; incubation for binding



antibody
(capture)




solid phase


excess of binding sites

Non-competitive immunoassay

analyte is bound; in two-step assay:
sample is washed away with excess
of analyte




Non-competitive immunoassay




Non-competitive immunoassay

labeled antibody is bound;
excess is washed away




Non-competitive immunoassay




Enzyme-linked immunosorbent assay (ELISA)

Thorough **washing steps** required




A. Coating anti-IgG

Non-covalent absorption of capture antibody to polystyrene surface (microtiter plate)




B. Blocking

Block surface with BSA or detergents to prevent non-specific binding of other proteins



C. React sample antigen

Add sample that contains the antigen (the analyte), e.g. tumor markers, viruses, or antibodies in serum.



D. React POx labelled secondary antibody

1. Add enzyme-labeled detection antibody (e.g. horseradish peroxidase); wash
2. Add chromogenic reagent (e.g. TMB)
3. Add "stop solution" (e.g. H_2SO_4)

Blocking is essential to avoid non-spec. binding

Normal serum

Normal serum (1-5% w/v) carries antibodies that bind to reactive sites and prevent non-specific binding of the secondary antibody. Serum is rich in albumin and other proteins that readily bind to non-specific protein binding sites of the sample.

Protein solutions

Blocking buffers often contain proteins such as bovine serum albumin (BSA), gelatin or nonfat dry milk (1-5% w/v). These inexpensive and readily available proteins are present in large excess compared to the antibody, so they compete with the latter for binding to nonspecific sites in the sample. Many labs developed homemade blocking buffers. It is important that blocking buffers are free of precipitates and other contaminants that can interfere with the detection.

Commercial buffers

Ready-made blocking buffers can contain highly purified single proteins or proprietary protein-free compounds. Many options are available that perform better than gelatin, casein or other proteins used alone, and they have improved shelf lives compared to homemade preparations.

Blocking tips

- Monitor both background (negative control) and signal strength (positive control) with various blocking reagents.
- Choose the blocking buffer that yields the highest signal-to-noise ratio.
- Ensure that there are no substances in the blocking buffer that interfere with a particular assay. Non-fat dry milk, for example, contains biotin and is inappropriate for use with any detection system that includes a biotin-binding protein.
- For optimal assay conditions, use the same blocking buffer for diluting the antibody that is used for the blocking step.


Enzyme-linked immunosorbant assay (ELISA)

Enzyme	Properties	
peroxidase galactosidase	rarely found in biosamples, high activity	} very common
phosphatase glucose oxidase	rarely found in biosamples, moderate activity	
catalase	high activity but often present in samples	} less suitable
protease	low activity	


=> Effect: strong signal amplification
(one enzyme label generates 100 - 1000 chromophores / fluorophores per second!)

Enzyme-mediated signal generation


(a) a chromogenic substrate (3,3',5,5'-Tetramethyl-benzidine (TMB)):



Stops the enzyme reaction:
Endpoint measurement




(b) a fluorogenic substrate:




- Coloration depends on the amount of enzyme-labeled secondary Ab;
- microtiter plate reader; absorbance at 450 nm expressed as Optical Density (OD)

Alternative non-competitive ELISA formats

(A) Indirect ELISA




(B) Sandwich ELISA



Immunometric assay


one-step assay



=> **analyte** is detected directly,
i.e. **signal** from immune complexes containing analyte

Immunometric assay


one-step assay



When capture antibody becomes saturated, free analyte in solution binds to the detection antibody and prevents it from binding to the antigen on the solid phase

Immunometric assay


two-step assay



=> avoids high dose hook effect

ELISA: data analysis


An-Ab binding:



$$K = \frac{[AnAb]}{[An][Ab]}$$

Surface-bound immune complex

4-parameter logistic function




Variables: "optical density" ($OD = absorbance$) and $[An]$

Fitted parameters:


- OD_{max} (signal at saturation)
- bg (background signal)
- C_{50} (midrange concentration)
- s (slope)

Detection limit of non-competitive assay



Immunoassay

dose-response curve



Limit of detection (LoD) vs. limit of quantification (LoQ)

LoD


The smallest concentration of an analyte in a test sample that we can easily distinguish from zero

LoQ

The smallest concentration of an analyte in a test sample that we can determine with acceptable repeatability and accuracy

Optimization of immunoassays

Non-optimized assay



Optimized assay

